Thermo Fisher Scientific (NYSE:TMO) Sets New 12-Month High - Time to Buy?

Key Points

• Thermo Fisher Scientific shares reached a new 52-week high of $648.44 and last traded near $640.64, above the analyst consensus target of $624.64. Analysts remain moderately bullish overall, though recent ratings were mixed, including upgrades from HSBC and downgrades from Deutsche Bank and Wells Fargo.
• The company reported strong quarterly results, with adjusted earnings of $6.03 per share and revenue of $11.99 billion, beating estimates and increasing revenue 10.5% year over year. Fiscal 2026 guidance calls for earnings per share of $24.93–$25.33.
• Thermo Fisher declared a quarterly dividend of $0.47 per share, equal to a 0.3% annualized yield, while insiders sold about $44.1 million of stock in the last quarter. Institutional investors and hedge funds own a substantial 89.23% of the company.

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report)'s share price hit a new 52-week high on Wednesday . The company traded as high as $648.44 and last traded at $640.6360, with a volume of 228048 shares changing hands. The stock had previously closed at $641.39.

Analyst Ratings Changes

Several research firms have recently commented on TMO. HSBC raised Thermo Fisher Scientific from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 1st. Deutsche Bank Aktiengesellschaft lowered Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Wednesday, September 9th. Wells Fargo & Company downgraded shares of Thermo Fisher Scientific from an "overweight" rating to an "underweight" rating in a research report on Wednesday, September 9th. Morgan Stanley raised their target price on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an "overweight" rating in a research note on Friday, July 24th. Finally, Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $624.64.

Thermo Fisher Scientific Stock Performance

The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The stock has a market cap of $237.07 billion, a P/E ratio of 34.50, a PEG ratio of 2.57 and a beta of 0.85. The stock has a fifty day simple moving average of $584.82 and a 200-day simple moving average of $520.14.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same period last year, the company posted $4.28 EPS. Thermo Fisher Scientific's revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.11%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Michael Shafer sold 25,500 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares in the company, valued at $12,596,400. This represents a 54.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 11,440 shares of the firm's stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total value of $7,014,092.80. Following the sale, the vice president directly owned 14,784 shares in the company, valued at approximately $9,064,366.08. This represents a 43.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 73,768 shares of company stock valued at $44,122,820. Insiders own 0.33% of the company's stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in shares of Thermo Fisher Scientific during the second quarter worth about $15,501,867,000. State Street Corp boosted its position in Thermo Fisher Scientific by 1.4% during the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company's stock worth $9,633,991,000 after acquiring an additional 229,630 shares during the last quarter. Capital World Investors grew its stake in shares of Thermo Fisher Scientific by 7.0% during the 4th quarter. Capital World Investors now owns 11,003,814 shares of the medical research company's stock worth $6,376,229,000 after acquiring an additional 718,669 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Thermo Fisher Scientific by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company's stock worth $4,728,129,000 after purchasing an additional 26,425 shares in the last quarter. Finally, Franklin Resources Inc. boosted its holdings in Thermo Fisher Scientific by 7.1% during the fourth quarter. Franklin Resources Inc. now owns 6,346,512 shares of the medical research company's stock worth $3,677,486,000 after purchasing an additional 420,841 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.